A Monotherapy Farnesyltransferase Inhibitor Study

The FDA has granted Breakthrough Therapy Designation for tipifarnib for the
treatment of patients with recurrent or metastatic HRAS-mutant HNSCC with variant
allele frequency ≥ 20% after disease progression on platinum-based chemotherapy.